Literature DB >> 21693251

A perspective on cirrhotic cardiomyopathy.

T Timoh1, M A Protano, G Wagman, M Bloom, T J Vittorio.   

Abstract

Cardiac dysfunction in patients with cirrhosis and potential clinical implications have long been known, but the pathophysiology and potential targets for therapeutic intervention are still under investigation and are only now becoming understood. The pathophysiological changes result in systolic dysfunction, diastolic dysfunction, and electrophysiological changes. Here, we aim to review cirrhotic cardiomyopathy from a cellular and physiological model and how these patients develop overt heart failure in the setting of stress, such as infection, ascites, and procedures including transjugular intrahepatic portosystemic shunt, portocaval shunts, and orthotopic liver transplantation. We will also review the most current, although limited, available therapeutic modalities.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21693251     DOI: 10.1016/j.transproceed.2011.01.188

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  13 in total

Review 1.  Cirrhosis in children and adolescents: An overview.

Authors:  Raquel Borges Pinto; Ana Claudia Reis Schneider; Themis Reverbel da Silveira
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Cirrhotic cardiomyopathy: a cardiologist's perspective.

Authors:  Natig Gassanov; Evren Caglayan; Nasser Semmo; Gero Massenkeil; Fikret Er
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

3.  Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis.

Authors:  Dimitrios S Karagiannakis; Jiannis Vlachogiannakos; Georgios Anastasiadis; Irini Vafiadis-Zouboulis; Spiros D Ladas
Journal:  Hepatol Int       Date:  2014-06-08       Impact factor: 6.047

4.  Correlation of Serum Cardiac Markers with Acute Decompensating Events in Liver Cirrhosis.

Authors:  Miaomiao Li; Zeqi Guo; Dan Zhang; Xiangbo Xu; Fernando Gomes Romeiro; Andrea Mancuso; Jingqiao Zhang; Ruirui Feng; Xinmiao Zhou; Cen Hong; Xingshun Qi
Journal:  Gastroenterol Res Pract       Date:  2020-09-24       Impact factor: 2.260

5.  Cardiac remodelling identified by cardiovascular magnetic resonance in patients with hepatitis C infection and liver disease.

Authors:  Phillip J Ngu; Michelle Butler; Alan Pham; Stuart K Roberts; Andrew J Taylor
Journal:  Int J Cardiovasc Imaging       Date:  2015-12-15       Impact factor: 2.357

6.  Cirrhotic cardiomyopathy: review of pathophysiology and treatment.

Authors:  Maneerat Chayanupatkul; Suthat Liangpunsakul
Journal:  Hepatol Int       Date:  2014-07       Impact factor: 6.047

7.  Cardiac function in patients with early cirrhosis during maximal beta-adrenergic drive: a dobutamine stress study.

Authors:  Aleksander Krag; Flemming Bendtsen; Emilie Kristine Dahl; Andreas Kjær; Claus Leth Petersen; Søren Møller
Journal:  PLoS One       Date:  2014-10-03       Impact factor: 3.240

8.  Prognostic Value of a New Marker of Ventricular Repolarization in Cirrhotic Patients.

Authors:  Angelo Antunes Salgado; Paulo Roberto Benchimol Barbosa; Alinne Gimenez Ferreira; Camila Aparecida de Souza Segrégio Reis; Carlos Terra
Journal:  Arq Bras Cardiol       Date:  2016-12       Impact factor: 2.000

9.  Herbal Supplement Ameliorates Cardiac Hypertrophy in Rats with CCl(4)-Induced Liver Cirrhosis.

Authors:  Ping-Chun Li; Yung-Wei Chiu; Yueh-Min Lin; Cecilia Hsuan Day; Guang-Yuh Hwang; Peiying Pai; Fuu-Jen Tsai; Chang-Hai Tsai; Yu-Chun Kuo; Hsiao-Chuan Chang; Jer-Yuh Liu; Chih-Yang Huang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-06       Impact factor: 2.629

10.  Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis.

Authors:  Soon Kyu Lee; Myeong Jun Song; Seok Hwan Kim; Hyo Jun Ahn
Journal:  Clin Mol Hepatol       Date:  2018-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.